---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-048277"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:11:29.810410+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics receives USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent

## Summary
- Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
- Patent expected to be granted within three months; would provide exclusivity at least into 2039 for stenoparib with DRP test.
- Allarity previously secured European and Australian patents for Stenoparib DRP; holds 18 granted patents for other drug-specific DRPs.
- Patent applications for Stenoparib DRP remain pending in Canada, Japan, China, and India.

## SEC filing metadata
- accession: 0001213900-26-048277
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026048277/0001213900-26-048277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026048277/ea0287908-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-048277
- JSON: https://secwatch.observer/filing/0001213900-26-048277.json
- Plain text: https://secwatch.observer/filing/0001213900-26-048277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.